MAGEA3 and non-small cell lung carcinoma: The efficacy of TTA targeting was also evaluated in a large clinical trial (NCT00480025) on NSCLC patients expressing MAGE-A3 treated with MAGE-A3 vaccine (AS15 proprietary adjuvant).